PERCIST in Perspective

Positron Emission tomography Response Criteria In Solid Tumors (PERCIST) version 1.0 was introduced in 2009 for objective assessment of tumor metabolic response using 18F-FDG PET/CT. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0 was published in 2016 to review and clarify some of the issues with the PERCIST. In this article, we reflect on the benefits and challenges of implementing PERCIST, and speculate on topics that could be discussed in PERCIST 1.1 in the future.

[1]  D. Choi,et al.  Prognostic Value of Volume-Based Metabolic Parameters Measured by 18F-FDG PET/CT of Pancreatic Neuroendocrine Tumors , 2014, Nuclear Medicine and Molecular Imaging.

[2]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[3]  J. Min,et al.  Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer , 2014, Nuclear Medicine and Molecular Imaging.

[4]  X. Ling,et al.  Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Jeanne Kowalski,et al.  Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy , 2009, Journal of Nuclear Medicine.

[6]  H. Nakanishi,et al.  Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. , 2016, Oncology letters.

[7]  Thomas Beez,et al.  Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma , 2013, The Journal of Nuclear Medicine.

[8]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Watabe,et al.  Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors , 2012, The Journal of Nuclear Medicine.

[10]  M. Gönen,et al.  Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Qiyong Ding,et al.  PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). , 2014, Journal of thoracic disease.

[12]  H. McArthur,et al.  The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST , 2016, The Journal of Nuclear Medicine.

[13]  Ji-Hoon Jung,et al.  Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer , 2015, Clinical nuclear medicine.

[14]  R. Wahl,et al.  Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging , 2014, The Journal of Nuclear Medicine.

[15]  H. Chung,et al.  Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma , 2016, European Radiology.

[16]  Martin A Lodge,et al.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. , 2016, Radiology.

[17]  Binsheng Zhao,et al.  Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[19]  Nai-Ming Cheng,et al.  TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib , 2016, European Journal of Nuclear Medicine and Molecular Imaging.